-
Product Insights
NewNeisseria gonorrhoeae Infections – Drugs In Development, 2024
Empower your strategies with our Neisseria gonorrhoeae Infections – Drugs In Development, 2024 report and make more profitable business decisions. Neisseria gonorrhoeae, the bacterium accountable for the sexually transmitted infection (STI) gonorrhea, is a notable public health issue causing substantial global morbidity in both resource-rich and resource-poor nations. The diagnosis and treatment of this infection entail considerable financial expenditures each year. Similar to other sexually transmitted infections (STIs), gonorrhea has a disproportionate impact on young adults. The obligate human pathogen N....
-
Product Insights
NewBacillary Dysentery (Shigellosis) – Drugs In Development, 2024
Empower your strategies with our Bacillary Dysentery (Shigellosis) – Drugs In Development, 2024 report and make more profitable business decisions. Shigella infection (shigellosis) is an intestinal disease caused by bacteria known as shigella. Symptoms include diarrhea, abdominal cramps, and fever. Predisposing factors include eating contaminated food, age, international travel, and being a homosexual man. Treatment includes antibiotics. The Bacillary Dysentery (Shigellosis) drugs in development market research report provide comprehensive information on the therapeutics under development for Bacillary Dysentery (Shigellosis), complete with...
-
Product Insights
NewHaemophilus influenzae Infections – Drugs In Development, 2024
Empower your strategies with our Haemophilus influenzae Infections – Drugs In Development, 2024 report and make more profitable business decisions. Haemophilus influenzae disease is an infection caused by the bacterium Haemophilus influenzae. Haemophilus influenzae is a bacteria characterized as a small, facultatively anaerobic, pleomorphic, and capnophilic gram-negative coccobacillus of the family Pasteurellaceae. It is a common cause of a variety of invasive and non-invasive bacterial infections. The Haemophilus influenzae Infections drugs in development market research report provide comprehensive information on the...
-
Product Insights
NewBacterial Vaginosis – Drugs In Development, 2024
Empower your strategies with our Bacterial Vaginosis – Drugs In Development, 2024 report and make more profitable business decisions. Bacterial vaginosis (BV), also known as vaginal bacteriosis, is a type of vaginal inflammation caused by the overgrowth of bacteria present in the vagina. Symptoms include vaginal itching, burning during urination, and watery and thin vaginal discharge. Treatment includes antibiotics. The Bacterial Vaginosis drugs in development market research report provide comprehensive information on the therapeutics under development for Bacterial Vaginosis, complete with...
-
Product Insights
NewKlebsiella Infections – Drugs In Development, 2024
Empower your strategies with our Klebsiella Infections – Drugs In Development, 2024 report and make more profitable business decisions. Klebsiella infections are caused by bacteria of the genus Klebsiella, with K. pneumoniae being the most common species associated with human infections. These bacteria are part of the normal flora in the human digestive tract and respiratory system but can cause various infections, especially in individuals with weakened immune systems or underlying health conditions. Klebsiella infections can manifest in different parts of...
-
Product Insights
NewEscherichia coli Infections – Drugs In Development, 2024
Empower your strategies with our Escherichia coli Infections – Drugs In Development, 2024 report and make more profitable business decisions. Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. E. coli infections are caused by coming into contact with the feces of humans or animals, or eating or drinking contaminated food or beverage. Symptoms include diarrhea, which may range from mild and watery to severe and bloody; abdominal cramping; pain or tenderness; nausea; and vomiting....
-
Product Insights
NewKlebsiella pneumoniae Infections – Drugs In Development, 2024
Empower your strategies with our Klebsiella pneumoniae Infections – Drugs In Development, 2024 report and make more profitable business decisions. Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs, and is very common in patients with underlying diseases like diabetes, chronic lung disease, and alcoholism. It is mostly a nosocomial infection that occurs in hospitalized patients with weakened immune systems. Symptoms include necrosis, inflammation, hemorrhage, chills, dizziness, high fever,...
-
Product Insights
NewTetanus – Drugs In Development, 2024
Empower your strategies with our Tetanus – Drugs In Development, 2024 report and make more profitable business decisions. Tetanus is a serious illness caused by Clostridium bacteria. Signs and symptoms of tetanus include spasms and stiffness in jaw muscles, difficulty swallowing, stiffness of abdominal muscles, fever, sweating, elevated blood pressure, and rapid heart rate. The predisposing factors include burns, surgical wounds, ear infections, swelling around the injury, and infected foot ulcers. Treatment includes antibiotics, sedatives, and beta blockers. The Tetanus drugs...
-
Product Insights
NewPertussis (Whooping Cough) – Drugs In Development, 2024
Empower your strategies with our Pertussis (Whooping Cough) – Drugs In Development, 2024 report and make more profitable business decisions. Pertussis, also known as whooping cough, is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Symptoms include runny nose, nasal congestion, sneezing, red watery eyes, and dry cough. Treatment includes antibiotics. The Pertussis (Whooping Cough) drugs in development market research report provide comprehensive information on the therapeutics under development for Pertussis (Whooping Cough), complete with analysis...
-
Product Insights
NewSepsis – Drugs In Development, 2024
Empower your strategies with our Sepsis – Drugs In Development, 2024 report and make more profitable business decisions. Sepsis is an illness in which the body has a severe response to bacteria or other germs. Sepsis occurs when chemicals released into the bloodstream to fight the infection trigger inflammation throughout the body. This response may be called systemic inflammatory response syndrome (SIRS). Symptoms of sepsis include chills, shaking, difficulty breathing, decrease in platelet count, abnormal heart pumping function, and abdominal pain....